UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 231

Sortiert nach

Direct Costs Of Diabetes Mellitus In Poland

Value in health, 2014-11, Vol.17 (7), p.A339-A339

Kawalec, P

2014

Volltextzugriff (PDF)

Indirect Costs of Diabetes Mellitus (Dm) From the Perspective of The Social Insurance Institution (Zus) In Poland

Value in health, 2014-11, Vol.17 (7), p.A340-A340

Kawalec, P

2014

Volltextzugriff (PDF)

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis

Rheumatology international, 2018-02, Vol.38 (2), p.189-201

2018

Volltextzugriff (PDF)

The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland

Expert review of pharmacoeconomics & outcomes research, 2015, Vol.15 (4), p.667-673

2015

Volltextzugriff (PDF)

The Indirect Costs of Multiple Sclerosis Associated With Absenteeism In Poland

Value in health, 2014-11, Vol.17 (7), p.A528-A529

2014

Volltextzugriff (PDF)

Costs of Absenteeism In Ankylosing Spondylitis Based On Real-Life Data From Poland's Social Insurance Institution Database In 2012

Value in health, 2014-11, Vol.17 (7), p.A529-A529

2014

Volltextzugriff (PDF)

Costs of Absenteeism In Psoriatic and Enteropathic Arthropathies Based On Real-Life Data From Poland's Social Insurance Institution Database In 2012

Value in health, 2014-11, Vol.17 (7), p.A528-A528

2014

Volltextzugriff (PDF)

Tyrosine Kinase Inhibitors (TKI) For The Treatment of Advanced Medullary Thyroid Carcinoma: A Systematic Review and Indirect Comparison

Value in health, 2016-11, Vol.19 (7), p.A708-A708

Kawalec, P

2016

Volltextzugriff (PDF)

Disease Activity, Quality of Life And Indirect Costs Associated With Ulcerative Colitis In Poland

Value in health, 2016-11, Vol.19 (7), p.A585-A585

Kawalec, P

2016

Volltextzugriff (PDF)

Efficacy and Safety Profile of Lenvatinib and Sorafenib in The Treatment of Adult Patients with Advanced Radioactive-Iodine-Refractory Differentiated Thyroid Cancer (RR-DTC)

Value in health, 2016-11, Vol.19 (7), p.A708-A708

Kawalec, P

2016

Volltextzugriff (PDF)

PCN3 - Efficacy and Safety Profile of Lenvatinib and Sorafenib in The Treatment of Adult Patients with Advanced Radioactive-Iodine-Refractory Differentiated Thyroid Cancer (RR-DTC)

Value in health, 2016-11, Vol.19 (7), p.A708-A708

Kawalec, P

2016

Volltextzugriff (PDF)

PSY60 - Disease Activity, Quality of Life And Indirect Costs Associated With Ulcerative Colitis In Poland

Value in health, 2016-11, Vol.19 (7), p.A585-A585

Kawalec, P

2016

Volltextzugriff (PDF)

PCN4 - Tyrosine Kinase Inhibitors (TKI) For The Treatment of Advanced Medullary Thyroid Carcinoma: A Systematic Review and Indirect Comparison

Value in health, 2016-11, Vol.19 (7), p.A708-A708

Kawalec, P

2016

Volltextzugriff (PDF)

CO70 Comparative Bayesian Network Meta-Analysis of BTKi-Specific Adverse Events in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Value in health, 2024-06, Vol.27 (6), p.S29-S30

2024

Volltextzugriff (PDF)

PSY114 - Recommendations and Reimbursement Status of Orphan Drugs In Ue Countries

Value in health, 2015-11, Vol.18 (7), p.A678-A679

Kawalec, P

2015

Volltextzugriff (PDF)

Recommendations and Reimbursement Status of Orphan Drugs In Ue Countries

Value in health, 2015-11, Vol.18 (7), p.A678-A679

Kawalec, P

2015

Volltextzugriff (PDF)

CO182 Efficacy of Venetoclax+Obinutuzumab+Ibrutinib Compared to Alternative Therapeutic Options in the First-Line Treatment of Chronic Lymphocytic Leukemia (Fit Population): A Systematic Review and Network Meta-Analysis

Value in health, 2023-12, Vol.26 (12), p.S46

2023

Volltextzugriff (PDF)

CO112 Efficacy and Safety of Venetoclax+Rituximab in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of Bayesian Network Meta-Analysis

Value in health, 2023-06, Vol.26 (6), p.S35-S35

2023

Volltextzugriff (PDF)

CO72 Risk of Richter Transformation in Relapsed/Refractory Cll: Results of Bayesian Network Meta-Analysis

Value in health, 2023-06, Vol.26 (6), p.S27-S28

2023

Volltextzugriff (PDF)

PSY130 - THE RELATIONSHIP BETWEEN DISEASE TYPE AND CONDITIONAL OR EXCEPTIONAL APPROVAL BY EMA FOR ORPHAN DRUGS IN 2017

Value in health, 2018-10, Vol.21, p.S458-S458

2018

Volltextzugriff (PDF)

HPR123 CEE: Brief Overview of Orphan Drug Reimbursement and Selected Clinical Characteristics

Value in health, 2022-12, Vol.25 (12), p.S254-S254

2022

Volltextzugriff (PDF)

Cost-Utility Analysis Of Hypertensive Treatment With Indapamide And Amlodipine Single-Pill Combination In The Polish Setting

Value in health, 2014-11, Vol.17 (7), p.A491-A491, Article A491

2014

Volltextzugriff (PDF)

Budget Impact Analysis Of Hypertensive Treatment With Indapamide And Amlodipine Single-Pill Combination In The Polish Setting

Value in health, 2014-11, Vol.17 (7), p.A479-A479, Article A479

2014

Volltextzugriff (PDF)

PDB50 - Indirect Costs of Diabetes Mellitus (Dm) From the Perspective of The Social Insurance Institution (Zus) In Poland

Value in health, 2014-11, Vol.17 (7), p.A340-A340

Kawalec, P.

2014

Volltextzugriff (PDF)

PDB42 - Direct Costs Of Diabetes Mellitus In Poland

Value in health, 2014-11, Vol.17 (7), p.A339-A339

Kawalec, P.

2014

Volltextzugriff (PDF)

1 – 25 von 231

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(228)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Direct Costs Of Diabetes Mellitus In Poland

Indirect Costs of Diabetes Mellitus (Dm) From the Perspective of The Social Insurance Institution (Zus) In Poland

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis

The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland

The Indirect Costs of Multiple Sclerosis Associated With Absenteeism In Poland

Costs of Absenteeism In Ankylosing Spondylitis Based On Real-Life Data From Poland's Social Insurance Institution Database In 2012

Costs of Absenteeism In Psoriatic and Enteropathic Arthropathies Based On Real-Life Data From Poland's Social Insurance Institution Database In 2012

Tyrosine Kinase Inhibitors (TKI) For The Treatment of Advanced Medullary Thyroid Carcinoma: A Systematic Review and Indirect Comparison

Disease Activity, Quality of Life And Indirect Costs Associated With Ulcerative Colitis In Poland

Efficacy and Safety Profile of Lenvatinib and Sorafenib in The Treatment of Adult Patients with Advanced Radioactive-Iodine-Refractory Differentiated Thyroid Cancer (RR-DTC)

PCN3 - Efficacy and Safety Profile of Lenvatinib and Sorafenib in The Treatment of Adult Patients with Advanced Radioactive-Iodine-Refractory Differentiated Thyroid Cancer (RR-DTC)

PSY60 - Disease Activity, Quality of Life And Indirect Costs Associated With Ulcerative Colitis In Poland

PCN4 - Tyrosine Kinase Inhibitors (TKI) For The Treatment of Advanced Medullary Thyroid Carcinoma: A Systematic Review and Indirect Comparison

CO70 Comparative Bayesian Network Meta-Analysis of BTKi-Specific Adverse Events in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

PSY114 - Recommendations and Reimbursement Status of Orphan Drugs In Ue Countries

Recommendations and Reimbursement Status of Orphan Drugs In Ue Countries

CO182 Efficacy of Venetoclax+Obinutuzumab+Ibrutinib Compared to Alternative Therapeutic Options in the First-Line Treatment of Chronic Lymphocytic Leukemia (Fit Population): A Systematic Review and Network Meta-Analysis

CO112 Efficacy and Safety of Venetoclax+Rituximab in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of Bayesian Network Meta-Analysis

CO72 Risk of Richter Transformation in Relapsed/Refractory Cll: Results of Bayesian Network Meta-Analysis

PSY130 - THE RELATIONSHIP BETWEEN DISEASE TYPE AND CONDITIONAL OR EXCEPTIONAL APPROVAL BY EMA FOR ORPHAN DRUGS IN 2017

HPR123 CEE: Brief Overview of Orphan Drug Reimbursement and Selected Clinical Characteristics

Cost-Utility Analysis Of Hypertensive Treatment With Indapamide And Amlodipine Single-Pill Combination In The Polish Setting

Budget Impact Analysis Of Hypertensive Treatment With Indapamide And Amlodipine Single-Pill Combination In The Polish Setting

PDB50 - Indirect Costs of Diabetes Mellitus (Dm) From the Perspective of The Social Insurance Institution (Zus) In Poland

PDB42 - Direct Costs Of Diabetes Mellitus In Poland

Suchergebnisse filtern